EpicentRx closes $35m series D financing to support development of small molecule immunotherapy and oncolytic viral platform

Image: EpicentRx has secured funds to support development of small molecule immunotherapy and oncolytic viral platform. Photo: courtesy of Arek Socha from Pixabay.